Classification of stimuli-responsive polymers as anticancer drug delivery systems

Drug Delivery

Volumn 22, Issue 2, 2015, Pages 145-155

  Taghizadeh, Bita ^a   Taranejoo, Shahrouz ^b   Monemian, Seyed Ali ^c   Moghaddam, Zoha Salehi ^d   Daliri, Karim ^e   Derakhshankhah, Hossein ^f   Derakhshani, Zaynab ^g  

^a UNIVERSITY OF TEHRAN   (Iran)

^b MONASH UNIVERSITY   (Australia)

^c Case Western Reserve University   (United States)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^g SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Anticancer; Cancer stimuli responsive polymers; Drug carriers; pH sensitive polymers; Smart delivery systems

Indexed keywords

2 HYDROXYETHYL METHACRYLATE; ANTINEOPLASTIC AGENT; CATHEPSIN B; CELL PENETRATING PEPTIDE; CHITOSAN; COPOLYMER; DEXTRAN; DRUG CARRIER; GLUTAMIC ACID; IRON OXIDE; LIPOSOME; MACROGOL; MATRIX METALLOPROTEINASE; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PEG 1000 PHOSPHOETHANOLAMINE; PHENYLALANINE; POLOXAMER; POLY(EPSILON CAPROLACTONE) POLYETHYLENE GLYCOL; POLY(N ISOPROPYLACRYLAMIDE); POLY(N ISOPROPYLACRYLAMIDE) CO N,N DIMETHYLACRYLAMIDE 118; POLYAMIDOAMINE; POLYETHYLENE GLYCOL BETA POLY [N (2 HYDROXYPROPYL) METHACRYLAMIDELACTATE]; POLYETHYLENEIMINE; POLYMER; STEARIC ACID; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; BIODEGRADABLE PLASTIC; DELAYED RELEASE FORMULATION; HYDROLASE; NANOMATERIAL; TUMOR PROTEIN;

CANCER TISSUE; CONJUGATE; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; HEAT SENSITIVITY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; HYDROGEL; HYPERTHERMIC THERAPY; MAGNETIC FIELD; MICELLE; MICROTUBULE; NONHUMAN; PH; PRIORITY JOURNAL; REVIEW; ADMINISTRATION AND DOSAGE; ANIMAL; CHEMISTRY; CLASSIFICATION; DELAYED RELEASE FORMULATION; DRUG EFFECTS; HEAT; HYDROLYSIS; METABOLISM; NANOTECHNOLOGY; NEOPLASMS; PHARMACEUTICS; RADIATION RESPONSE; SOLUBILITY; SOUND; THERAPEUTIC USE; TRENDS; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIODEGRADABLE PLASTICS; BIOPHARMACEUTICS; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HOT TEMPERATURE; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLASES; HYDROLYSIS; MAGNETIC FIELDS; NANOSTRUCTURES; NANOTECHNOLOGY; NEOPLASM PROTEINS; NEOPLASMS; POLYMERS; SOLUBILITY; SOUND; TUMOR MICROENVIRONMENT;

EID: 84921692313     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2014.887157     Document Type: Review

References (156)

1. Abulateefeh SR, Spain SG, Aylott JW, et al. (2011). Thermoresponsive polymer colloids for drug delivery and cancer therapy. Macromol Biosci 11:1722-34.
2. Akbarzadeh A, Samiei, M, Joo SW, et al. (2012). Synthesis, characterization and in vitro studies of doxorubicin-loaded magnetic nanoparticles grafted to smart copolymers on A549 lung cancer cell line. J Nanobiotechnology 10:46-58.
3. Alamdarnejad G, Sharif A, Taranejoo S, et al. (2013). Synthesis and characterization of thiolated carboxymethyl chitosan-graft-cyclodextrin nanoparticles as a drug delivery vehicle for albendazole. J Mater Sci Mater Med 24:1939-49.
4. Alani AW, Bae Y, Rao DA, Kwon GS. (2010). Polymeric micelles for the pH-dependent controlled, continuous low dose release of paclitaxel. Biomaterials 31:1765-72.
5. Aliaghaie M, Mirzadeh H, Dashtimoghadam E, Taranejoo S. (2012). Investigation of gelation mechanism of an injectable hydrogel based on chitosan rheological measurements for a drug delivery application. Soft Matter 8:7128-37.
6. Baghshawe KD, Begent RHJ. (1996). First clinical experience with ADEPT. Adv Drug Deliver Rev 22:365-7.
7. Barick KC, Singh S, Jadhav NV, et al. (2012). pH-responsive peptide mimic shell cross-linked magnetic nanocarriers for combination therapy. Adv Funct Mater 22:4975-84.
8. Bourne NK, Field JE. (1999). Shock-induced collapse and luminescence by cavities. Philos Trans Roy Soc A 357:295-311.
9. Boussif O, Lezoualc'h F, Zanta MA, et al. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 92:7297-301.
10. Bristow MR, Billingham ME, Mason JW, Daniels JR. (1978). Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873-9.
11. Chaterji S, Kwon IK, Park K. (2007). Smart polymeric gels: redefining the limits of biomedical devices. Prog Polym Sci 32:1083-122.
12. Chau Y, Padera RF, Dang NM, Langer R. (2006). Antitumor efficacy of a novel polymer-peptide-drug conjugate in human tumor xenograft models. Int J Cancer 118:1519-26.
13. Chen W, Du J. (2013). Ultrasound and pH dually responsive polymer vesicles for anticancer drug delivery. Sci Rep 3:2162-70.
14. Chen YC, Liao LC, Lu PL, et al. (2012). The accumulation of dual pH and temperature responsive micelles in tumors. Biomaterials 33: 4576-88.
15. Cheng YC, Chen LM, et al. (2009). Lipopolysaccharide upregulates uPA, MMP-2 and MMP-9 via ERK1/2 signaling in H9c2 cardiomyoblast cells. Mol Cell Biochem 325:15-23.
16. Chiang, WH, Ho VT, Chen HH, et al. (2013). Superparamagnetic hollow hybrid nanogels as a potential guidable vehicle system of stimulimediated MR imaging and multiple cancer therapeutics. Langmuir 29: 6434-43.
17. Coffey DS, Getzenberg RH, DeWeese TL. (2006). Hyperthermic biology and cancer therapies: a hypothesis for the "Lance Armstrong effect". JAMA 296:445-8.
18. Cui W, Lu X, Cui K, et al. (2012). Dual-responsive controlled drug delivery based on ionically assembled nanoparticles. Langmuir 28: 9413-20.
19. Dayton PA, Pearson D, Clark J, et al. (2004). Ultrasonic analysis of peptide- and antibody-targeted microbubble contrast agents for molecular imaging of alphavbeta3-expressing cells. Mol Imaging 3: 125-34.
20. Deng Z, Zhen Z, Hu X, et al. (2011). Hollow chitosan-silica nanospheres as pH-sensitive targeted delivery carriers in breast cancer therapy. Biomaterials 32:4976-86.
21. Deryugina EI, Quigley JP. (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25:9-34.
22. Desale SS, Cohen SM, Zhao Y, et al. (2013). Biodegradable hybrid polymer micelles for combination drug therapy in ovarian cancer. J Control Release 171:339-48.
23. Dong DW, Tong SW, Qi XR. (2013). Comparative studies of polyethylenimine-doxorubicin conjugates with pH-sensitive and pH-insensitive linkers. J Biomed Mater Res A 101:1336-44.
24. Douziech-Eyrolles L, Marchais H, Hervé K, et al. (2007). Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine 2: 541-50.
25. Duncan R, Gac-Breton S, Keane R, et al. (2001). polymer-drug conjugates, PDEPT and PELT: basic principles for design and tranfer from the laboratory to clinic. J Control Release 74:135-46.
26. Duncan R, Satchi-Fainaro R. (2002). Pharmacuetical compositions containing antibody-enzyme conjugates in combination with prodrugs. United States Patent, USA.
27. Duncan R. (2006). Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688-701.
28. Edelman ER, Brown L, Taylor J, Langer R. (1987). In vitro and in vivo kinetics of regulated drug release from polymer matrices by oscillating magnetic fields. J Biomed Mater Res 21: 339-53.
29. Engin K. (1996). Biological rationale and clinical experience with hyperthermia. Control Clin Trials 17:316-42.
30. Etrych T, Jelínková M, Ríhová B, Ulbrich K. (2001). New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties. J Control Release 73:89-102.
31. Fang F, Gong C, Qian Z, et al. (2009). Honokiol nanoparticles in thermosensitive hydrogel: therapeutic effects on malignant pleural effusion. ACS Nano 3:4080-8.
32. Fenton RG, Longo DI. (1998). Cell biology of cancer. In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DI, eds. Harrison's internal medicine. New York: McGraw Hill, 505-11.
33. Field SB, Bleehen NM. (1979). Hyperthermia in the treatment of cancer. Cancer Treat Rev 6:63-94.
34. Filippousi M, Papadimitriou SA, Bikiaris DN, et al. (2013). Novel coreshell magnetic nanoparticles for Taxol encapsulation in biodegradable and biocompatible block copolymers: preparation, characterization and release properties. Int J Pharm 448: 221-30.
35. Fleige E, Quadir MA, Haag R. (2012). Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications. Adv Drug Deliv Rev 64:866-84.
36. Fong SW, Klaseboer E, Khoo BC. (2008). Interaction of microbubbles with high intensity pulsed ultrasound. J Acoust Soc Am 13:1784-93.
37. Gabriel D, Zuluaga MF, Lange N. (2011). On the cutting edge: proteasesensitive prodrugs for the delivery of photoactive compounds. Photochem Photobiol Sci 10:689-703.
38. Gao Z, Fain HD, Rapoport N. (2004). Ultrasound-enhanced tumor targeting of polymeric micellar drug carriers. Mol Pharm 1: 317-30.
39. Gao ZG, Fain HD, Rapoport N. (2005). Controlled and targeted tumor chemotherapy by micellar-encapsulated drug and ultrasound. J Control Release 102:203-22.
40. García-Román J, Zentella-Dehesa A. (2013). Vascular permeability changes involved in tumor metastasis. Cancer Lett 335:259-69.
41. Gil ES, Hudson SA. (2004). Stimuli-reponsive polymers and their bioconjugates. Prog Polym Sci 29:1173-222.
42. Glover AL, Bennett JB, Pritchett JS, et al. (2013). Magnetic heating of iron oxide nanoparticles and magnetic micelles for cancer therapy. IEEE Trans Magn 49:231-5.
43. Gong C, Wei XW, Wang XH, et al. (2010). Biodegradable self-assembled PEG-PCL-PEG micelles for hydrophobic honokiol delivery: I. Preparation and characterization. Nanotechnology 21: 215103.
44. Gong CY, Dong PW, Shi S, et al. (2009a). Thermosensitive PEG-PCL- PEG hydrogel controlled drug delivery system: sol-gel-sol transition and in vitro drug release study. J Pharm Sci 98:3707-17.
45. Gong CY, Shi S, Peng XY, et al. (2009b). Biodegradable thermosensitive injectable PEG-PCL-PEG hydrogel for bFGF antigen delivery to improve humoral immunity. Growth Factors 27:377-83.
46. Grifith GL, Hansen HJ. (2002). Methods and compositions for increasing the target-specific toxicity of a chemotherapy drug. United States Patent, USA.
47. Guo M, Yan Y, Zhang HK, et al. (2008). Magnetic and pH-responsive nanocarriers with multilayer core-shell architecture for anticancer drug delivery. J Mater Chem 18: 5104-12.
48. Hoffman AS. (2013). Stimuli-responsive polymers: Biomedical applications and challenges for clinical translation. Adv Drug Delivery Rev 65:10-16.
49. Hoffman S. (2004). Biomaterials science. 2nd ed. London: Academic Press.
50. Hovgaard L, Brøndsted H. (1995). Dextran hydrogels for colon-specific drug delivery. J Control Release 36:159-66.
51. Hu FQ, Zhang Y-Y, You J, et al. (2012). pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy. Mol Pharm 9:2469-78.
52. Issels RD. (1995). Regional hyperthermia combined with systemic chemotherapy of locally advanced sarcomas: preclinical aspects and clinical results. Recent Res Cancer Res 138:81-90.
53. Jain A, Gupta Y, Jain SK. (2007). Perspectives of biodegradable natural polysaccharides for site-specific drug delivery to the colon. J Pharm Pharm Sci 10:86-128.
54. Kassan DG, Lynch AM, Stiller MJ. (1996). Physical enhancement of dermatologic drug delivery: iontophoresis and phonophoresis. J Am Acad Dermatol 34:657-66.
55. Kataoka K, Itaka K, Nishiyama N, et al. (2005). Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Symp Ser (Oxf) 49:17-18.
56. Kennedy JE, Ter Haar GR, Cranston D. (2003). High intensity focused ultrasound: surgery of the future? Br J Radiol 76:590-9.
57. Kheirolomoom A, Mahakian LM, Lai CY, et al. (2010). Copperdoxorubicin as a nanoparticle cargo retains efficacy with minimal toxicity. Mol Pharm 7:1948-58.
58. Klaikherd A, Nagamani C, Thayumanavan S. (2009). Multi-stimuli sensitive amphiphilic block copolymer assemblies. J Am Chem Soc 131:4830-8.
59. Kopansky E, Shamay Y, David A. (2011). Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer. J Drug Target 19:933-43.
60. Kopecek J, Kopecková P, Minko T, et al. (2001). Water soluble polymers in tumor targeted delivery. J Control Release 74:147-58.
61. Kost J, Langer R. (2001). Responsive polymeric delivery systems. Adv Drug Deliv Rev 46:125-48.
62. Lanza GM, Wallace KD, Scott MJ, et al. (1996). A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 94:3334-40.
63. Lavignac N, Nicholls JL, Ferruti P, et al. (2009). Poly(amidoamine) conjugates containing doxorubicin bound via an acid-sensitive linker. Macromol Biosci 9:480-7.
64. Law MP. (1982). Prospects for hyperthermia in cancer therapy. Radiography 48:209-19.
65. Lee ES, Gao Z, Kim D, et al. (2008). Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance. J Control Release 129:228-36.
66. Li W, Li JF, Gao J, et al. (2011). The fine-tuning of thermosensitive and degradable polymer micelles for enhancing intracellular uptake and drug release in tumors. Biomaterials 32:3832-44.
67. Li W, Zhao H, Qian W, et al. (2012). Chemotherapy for gastric cancer by finely tailoring anti-Her2 anchored dual targeting immunomicelles. Biomaterials 33:5349-62.
68. Liang L, Lin SW, Dai W, et al. (2012). Novel cathepsin B-sensitive paclitaxel conjugate: higher water solubility, better efficacy and lower toxicity. J Control Release 160:618-29.
69. Liu TY, Hu SH, Liu KH, et al. (2008). Study on controlled drug permeation of magnetic-sensitive ferrogels: effect of Fe3O4 and PVA. J Control Release 126:228-36.
70. Liz-Marzán LM, Giersig M, Mulvaney P. (1999). Synthesis of nanosized gold-silica core-shell particles. Langmuir 12:4329-35.
71. LoPachin RM. (2005). Acrylamide neurotoxicity: neurological, morhological and molecular endpoints in animal models. Adv Exp Med Biol 561:21-37.
72. Lu C, Xing MM, Zhong W. (2011). Shell cross-linked and hepatocytetargeting nanoparticles containing doxorubicin via acid-cleavable linkage. Nanomedicine 7:80-7.
73. MacEwan SR, Callahan DJ, Chilkoti A. (2010). Stimulus-responsive macromolecules and nanoparticles for cancer drug delivery. Nanomedicine (Lond) 5:793-806.
74. Maeda H, Sawa T, Konno T. (2001). Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug smancs. J Control Release 74:47-61.
75. Maeda H, Wu J, Sawa T, et al. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 65:271-84.
76. Mahmoudi M, Sant S, Wang B, et al. (2011). Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. Adv Drug Deliv Rev 63:24-46.
77. Majedi FS, Hasani-Sadrabadi MM, VanDersarl JJ, et al. (2013). On-Chip Fabrication of Paclitaxel-Loaded Chitosan Nanoparticles for Cancer Therapeutics. Adv Funct Mater. 24:432-41.
78. Mansour AM, Drevs J, Esser N, et al. (2003). A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2. Cancer Res 63:4062-6.
79. Matsumura Y, Maeda H. (1986). A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 46:6387-92.
80. Meenach SA, Shapiro JM, Hilt JZ, Anderson KW. (2013). Characterization of PEG-iron oxide hydrogel nanocomposites for dual hyperthermia and paclitaxel delivery. J Biomater Sci Polym Ed 24:1112-26.
81. Meers P. (2001). Enzyme-activated targeting of liposomes. Adv Drug Deliv Rev 53:265-72.
82. Meyer DE, Shin BC, Kong GA, et al. (2001). Drug targeting using thermally responsive polymers and local hyperthermia. J Control Release 74:213-24.
83. Moin K, Cao L, Day NA, et al. (1998). Tumor cell membrane cathepsin B. Biol Chem 379:1093-9.
84. Muller RH, Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs - a review of drug nanocrystal technology and lipid nanoparticles. J Biotechnol 113:151-70.
85. Mura S, Nicolas J, Couvreur P. (2013). Stimuli responsive nanocarriers for drug delivery. Nat Mater 12:991-1003.
86. Nahire R, Paul S, Scott MD, et al. (2012). Ultrasound enhanced matrix metalloproteinase- 9 triggered release of contents from echogenic liposomes. Mol Pharm 9:2554-64.
87. Oh KS, Lee H, Kim JY, et al. (2013). The multilayer nanoparticles formed by layer by layer approach for cancer-targeting therapy. J Control Release 165:9-15.
88. Ojugo ASE, Mcsheehy PMJ, Mcintyre DJO, et al. (1999). Measurement of the extracellular pH of solid tumors in mice by magnetic resonance spectroscopy: a comparison of exogenous 19F and 31P probes. NMR Biomed 12:495-504.
89. Park JE, Lenter MC, Zimmermann RN, et al. (1999). Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274:36505-12.
90. Park H, Song IH, Kim JH, Kim WS. (1998). Preparation of thermally denatured albumin gel and its pH-sensitive swelling. Int J Pharm 175: 231-6.
91. Pradhan P, Giri J, Rieken F, et al. (2010). Targeted temperature sensitive magnetic liposomes for thermo-chemotherapy. J Control Release 142: 108-21.
92. Praga C, Beretta G, Labianca R. (1980). Cardiac toxicity from antitumor therapy. Oncology 37:51-8.
93. Qiu Y, Park K. (2001). Environment-sensitive hydrogels for drug delivery. Adv Drug Deliv Rev 53:321-39.
94. Qu JB, Shao HH, Jing GL, Huang F. (2013). PEG-chitosan-coated iron oxide nanoparticles with high saturated magnetization as carriers of 10-hydroxycamptothecin: preparation, characterization and cytotoxicity studies. Colloids Surf B Biointerfaces 102: 37-44.
95. Ranjan A, Jacobs GC, Woods DL, et al. (2012). Image-guided drug delivery with magnetic resonance guided high intensity focused ultrasound and temperature sensitive liposomes in a rabbit V × 2 tumor model. J Control Release 158:487-94.
96. Rapoport N, Gao Z, Kennedy A. (2007). Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 99:1095-106.
97. Rapoport N, Pitt WG, Sun H, Nelson JL. (2003). Drug delivery in polymeric micelles: from in vitro to in vivo. J Control Release 91: 85-95.
98. Rejinold NS, Muthunarayanan M, Divyarani VV, et al. (2011). Curcumin-loaded biocompatible thermoresponsive polymeric nanoparticles for cancer drug delivery. J Colloid Interface Sci 360:39-51.
99. Rijcken CJ, Hofman JW, van Zeeland F, et al. (2007). Photosensitiserloaded biodegradable polymeric micelles: preparation, characterisation and in vitro PDT efficacy. J Control Release 124:144-53.
100. Rijcken CJ, Veldhuis TF, Ramzi A, et al. (2005). Novel fast degradable thermosensitive polymeric micelles based on PEG-block-poly(N-(2-hydroxyethyl)methacrylamide-oligolactates). Biomacromolecules 6:2343-51.
101. Ruoslahti E, Bhatia SN, Sailor MJ. (2010). Targeting of drugs and nanoparticles to tumors. J Cell Biol 188:759-68.
102. Saad AH, Hahn GM. (1989). Ultrasound enhanced drug toxicity on Chinese hamster ovary cells in vitro. Cancer Res 49:5931-4.
103. Sawant RM, Hurley JP, Salmaso S, et al. (2006). "SMART" drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem 17:943-9.
104. Schmidt AM. (2007). Thermoresponsive magnetic colloids. Colloid Polym Sci 285:953-66.
105. Schroeder A, Honen R, Turjeman K, et al. (2009). Ultrasound triggered release of cisplatin from liposomes in murine tumors. J Control Release 137:63-8.
106. Sengupta S, Sasisekharan R. (2007). Exploiting nanotechnology to target cancer. Br J Cancer 96:1315-19.
107. Sirova M, Mrkvan T, Etrych T, et al. (2010). Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model. Pharm Res 27:200-8.
108. Soga O, van Nostrum CF, Fens M, et al. (2005). Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery. J Control Release 103:341-53.
109. Soga O, van Nostrum CF, Ramzi A, et al. (2004). Physicochemical characterization of degradable thermosensitive polymeric micelles. Langmuir 20:9388-95.
110. Sonawane ND, Szoka Jr FC, Verkman AS. (2003). Chloride accumulation and swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. J Biol Chem 278:44826-31.
111. Soppimath KS, Liu LH, Seow WY, et al. (2007). Multifunctional core/shell nanoparticles self-assembled from pH-induced thermosensitive polymers for targeted intracellular anticancer drug delivery. Adv Mater 17:355-62.
112. Soppimath KS, Tan DCW, Yang YY. (2005). pH-triggered thermally responsive polymer core-shell nanoparticles for drug delivery. Adv Mater 17: 318-23.
113. Spallarossa P, Altieri P, Garibaldi S, et al. (2006). Matrix metallopro-teinase- 2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. Cardiovasc Res 69: 736-45.
114. Sparano JA. (1999). Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics. Semin Oncol 26(3 Suppl 9):14-19.
115. Stride EP, Coussios CC. (2010). Cavitation and contrast: the use of bubbles in ultrasound imaging and therapy. Proc Inst Mech Eng H 224:171-91.
116. Stubbs M, Mcsheehy RMJ, Griffiths JR, Bashford L. (2000). Causes and consequences of tumor acidity and implications for treatment. Mol Med Today 6:15-19.
117. Szabó D, Czakó-Nagy II, Zrínyi M, Vértes A. (2000). Magnetic and Mossbauer Studies of Magnetite-Loaded Polyvinyl Alcohol Hydrogels. J Colloid Interface Sci 221:166-72.
118. Ta T, Convertine AJ, Reyes CR, et al. (2010). Thermosensitive liposomes modified with poly(N-isopropylacrylamide-co-propylacrylic acid) copolymers for triggered release of doxorubicin. Biomacromolecules 11:1915-20.
119. Tachibana K, Uchida T, Hisano S, Morioka, S. (1997). Eliminating adult T-cell leukaemia cells with ultrasound. Lancet 349:325-30.
120. Tachibana K, Uchida T, Ogawa K, et al. (1999). Induction of cellmembrane porosity by ultrasound. Lancet 353:1409.
121. Tachibana K. (2004). Emerging technologies in therapeutic ultrasound: thermal ablation to gene delivery. Hum Cell 17:7-15.
122. Takahashi A, Yamamoto Y, Yasunaqa M, et al. (2013). NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci 104:920-5.
123. Talelli M, Iman M, Varkouhi AK, et al. (2010a). Core-crosslinked polymeric micelles with controlled release of covalently entrapped doxorubicin. Biomaterials 31:7797-804.
124. Talelli M, Rijcken CJ, van Nostrum CF, et al. (2010b). Micelles based on HPMA copolymers. Adv Drug Deliv Rev 62:231-9.
125. Taranejoo S, Monemian S, Moghri M, Derakhshankhah H. (2014). Development of ultrasmall chitosan/succinyl b-cyclodextrin nanoparticles as a sustained protein-delivery system. J Appl Polym Sci 131: 39648-53.
126. Terada T, Iwai M, Kawakami S, et al. (2006). Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release 111:333-42.
127. Torchilin V. (2009). Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 71:431-44.
128. Über den Einfluss WB. (1866). welchen heftigere Erysipelen zuweilen auf organisierte Neubildunge ausüben. Verhandlungen des naturhistorischen Vereines der preussischen Rheinlande und Westphalens 23: 28-30.
129. Ulbrich K, Etrych T, Chytil P, et al. (2003). HPMA copolymers with pH-controlled release of doxorubicin: in vitro cytotoxicity and in vivo antitumor activity. J Control Release 87:33-47.
130. Urano M, Kuroda M, Nishimura Y. (1999). For the clinical application of thermochemotherapy given at mild temperatures. Int J Hyperthermia 15:79-107.
131. Urban-Klein B, Werth S, Abuharbeid S, et al. (2005). RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther 12:461-6.
132. Utani A, Momota Y, Endo H, et al. (2003). Laminin alpha 3 LG4 module induces matrix metalloproteinase-1 through mitogen-activated protein kinase signaling. J Biol Chem 278:34483-90.
133. Van Nostrum CF, Neradovic D, Soga O, Hennink WE. (2006). Polymeric micelles with transient stability: a novel delivery concept. ACS Symposium Series. 923:40-54.
134. Vaupel P, Kallinowski F, Okunieff P. (1989). Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449-65.
135. Vetvicka D, Hruby M, Hovorka O, et al. (2009). Biological evaluation of polymeric micelles with covalently bound doxorubicin. Bioconjug Chem 20:2090-7.
136. Villa R, Cerroni B, Viganò L, et al. (2013). Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells. Colloids Surf B Biointerfaces 1:434-42.
137. Wahajuddin, Arora S. (2012). Superparamagnetic iron oxide nanoparticles: magnetic nanoplatforms as drug carriers. Int J Nanomedicine 7: 3445-71.
138. Wan CP, Jackson JK, Pirmoradi FN, et al. (2012). Increased accumulation and retention of micellar paclitaxel in drug-sensitive and P-glycoprotein-expressing cell lines following ultrasound exposure. Ultrasound Med Biol 38:736-44.
139. Wang SY, Liu MC, Kang KA. (2013). Magnetic nanoparticles and thermally responsive polymer for targeted hyperthermia and sustained anti-cancer drug delivery. Adv Exp Med Biol 765:315-21.
140. Wang Y, Gong C, Yang L, et al. (2010). 5-FU-hydrogel inhibits colorectal peritoneal carcinomatosis and tumor growth in mice. BMC Cancer 10:402.
141. Welz MM, Ofner III CM. (1992). Examination of self-crosslinked gelatin as a hydrogel for controlled release. J Pharm Sci 81:85-90.
142. Wong C, Stylianopoulos T, Cui J, et al. (2011). Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc Natl Acad Sci USA 108:2426-31.
143. Yang HW, Hua MY, Liu HL, et al. (2011). Self-protecting core-shell magnetic nanoparticles for targeted, traceable, long half-life delivery of BCNU to gliomas. Biomaterials 32:6523-32.
144. Yang L, Chu JS, Fix JA. (2002). Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 235:1-15.
145. Yin T, Wang P, Li J, et al. (2013). Ultrasound-sensitive siRNA-loaded nanobubbles formed by hetero-assembly of polymeric micelles and liposomes and their therapeutic effect in gliomas. Biomaterials 34: 4532-43.
146. Yumita N, Nishigaki R, Umemura K, et al. (1994). Sonochemical activation of hematoporphyrin: an ESR study. Radiat Res 138:171-6.
147. Zhang LY, Guo R, Yang M, et al. (2007). Thermo and pH dual-responsive nanoparticles for anti-cancer drug delivery. Adv Mater 19:2988-92.
148. Zhao ZH, Huang DT, Yin ZY, et al. (2012). Magnetite nanoparticles as smart carriers to manipulate the cytotoxicity of anticancer drugs: magnetic control and pH-responsive release. J Mater Chem 22: 15717-25.
149. Zheng W, Zhang Y, Ma D, et al. (2012). (+/-)Equol inhibits invasion in prostate cancer DU145 cells possibly via down-regulation of matrix metalloproteinase-9, matrix metalloproteinase-2 and urokinase-type plasminogen activator by antioxidant activity. J Clin Biochem Nutr 51: 61-7.
150. Zhu L, Huo Z, Wang L, et al. (2009). Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharm 370:136-43.
151. Zhu L, Kate P, Torchilin VP. (2012a). Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 6:3491-8.
152. Zhu L, Mahato RI. (2010). Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv 7:1209-26.
153. Zhu L, Wang T, Perche F, et al. (2013). Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci USA 110:17047-52.
154. Zhu L, Ye Z, Cheng K, et al. (2008). Site-specific delivery of oligonucleotides to hepatocytes after systemic administration. Bioconjug Chem 19:290-8.
155. Zhu S, Hong M, Zhang L, et al. (2010). PEGylated PAMAM dendrimerdoxorubicin conjugates: in vitro evaluation and in vivo tumor accumulation. Pharm Res 27:161-74.
156. Zhu S, Lansakara-P DS, Li X, Cui Z. (2012b). Lysosomal delivery of a lipophilic gemcitabine prodrug using novel acid-sensitive micelles improved its antitumor activity. Bioconjug Chem 23: 966-80.